Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Medicure increases Q2 revenue thanks to ZYPITAMAG and pharmacies, reports larger net loss

Medicure reported Q2 2026 net revenue of CAD 7.4 million (+10.4% vs. year‑ago), driven by ZYPITAMAG and its pharmacy network, which accounted for about 79.9% of revenue. Adjusted EBITDA improved to CAD 172,000, but the reported net loss widened to CAD 1.4 million, mainly due to a CMS-related rebate liability (CAD 864,000) and higher R&D spending for the Phase III MC-1 program. AGGRASTAT sales fell 61.1% on intensified generic competition, and cash declined to CAD 1.8 million. Management emphasizes a focus on further growth of ZYPITAMAG, integration of the pharmacies and progress on MC-1, but did not provide formal guidance. » Altro su de.investing.com
Medicure records 43.6% revenue growth in Q1 2026

Medicure reports a 43.6% revenue increase in Q1 2026 to CAD 7.9 million and narrowed its net loss to CAD 406,000, or -0.04 CAD per share. Growth was driven mainly by ZYPITAMAG (revenue through insurance channels +150.3%) and pharmacy acquisitions, while AGGRASTAT declined 42.4% due to generic competition. Cash fell to CAD 1.5 million; the company forecasts revenues of CAD 25.06 million for 2026 and CAD 28.2 million for 2027 and is focusing on expanding its pharmacy business. » Altro su de.investing.com
Medicure increases revenue, stock falls by one-third after large losses

Medicure reported Q4 2025 net revenue of 8.5 million CAD, an increase of 44.07% year‑over‑year, but the net loss widened to 7.1 million CAD. The stock plunged 33.33% to $0.45 and approached its 52‑week low. The pharmacy segment contributed 67.47% of revenue, and the cash position fell to 3.8 million CAD. Management emphasizes continued R&D commitment in MC‑1 and synergies from recent acquisitions to improve margins. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Medicure ha già distribuito 91,14€ di dividendi. L'ultimo pagamento è avvenuto a novembre 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Medicure ha registrato ricavi pari a 4.58m€ e un utile netto di −880.66k€

(EUR)	giu 2026	YoY
Ricavi	+4.58m	10,14%
Utile lordo	+1.97m	7,92%
Utile netto	−880.66k	79,69%
EBITDA	−355.84k	901,17%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+8.33m€
Numero di azioni	10.44m
Massimo/minimo a 52 settimane	+0,83€ - +0,58€
Dividendi	No
Beta	1,04
Rapporto P/E	−1,83
Rapporto PEG	+0,02
Rapporto P/B	+1,17
Rapporto P/S	+0,42

Profilo aziendale

Medicure Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Erforschung, Entwicklung und Vermarktung von Humantherapien für den kardiovaskulären Markt in Kanada und den Vereinigten Staaten beschäftigt. Das Unternehmen vermarktet und vertreibt AGGRASTAT-Injektion, einen Glykoprotein-GP IIb/IIIa-Rezeptor-Antagonisten für die Behandlung des akuten Koronarsyndroms, einschließlich instabiler Angina pectoris und Nicht-Q-Wellen-Myokardinfarkt. Außerdem bietet es ZYPITAMAG zur Behandlung von Patienten mit primärer Hyperlipidämie oder gemischter Dyslipidämie an. Darüber hinaus bietet das Unternehmen ReDS an, ein nicht-invasives medizinisches Gerät, das die Messung von Lungenflüssigkeit für das Management von kongestiver Herzinsuffizienz ermöglicht. Darüber hinaus bietet das Unternehmen Natriumnitroprussid-Injektionen zur Senkung des Blutdrucks bei erwachsenen und pädiatrischen Patienten in hypertensiven Krisen sowie zur Erzeugung einer kontrollierten Hypotonie zur Verringerung von Blutungen bei Operationen und zur Behandlung von akuter Herzinsuffizienz an. Das Unternehmen bietet seine Produkte sowohl über den Apothekenhandel als auch online an. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in Winnipeg, Kanada.

Nome	Medicure
CEO	Albert David Friesen
Sede centrale	Winnipeg, mb Australia
Sito web	medicure.com
Settore	Servizi di pubblica utilità
Industria	Prodotti chimici
Quotazione in borsa	09/08/2018
Dipendenti	23